Incyte Announces Updated Data for Ruxolitinib Cream Accepted for Presentation at the 2021 Revolutionizing Atopic Dermatitis (...
12 Junio 2021 - 4:01PM
Business Wire
-- First presentation of long-term safety and
disease control data from Phase 3 TRuE-AD studies of ruxolitinib
cream in atopic dermatitis
Incyte (Nasdaq:INCY) today announced that multiple abstracts
highlighting updated data for ruxolitinib cream, an investigational
topical JAK1/JAK2 inhibitor, in patients with atopic dermatitis
(AD) will be presented at the upcoming 2021 Revolutionizing Atopic
Dermatitis (RAD) Virtual Conference, held on June 13, 2021.
“Atopic dermatitis, the most common type of eczema, can be
difficult to manage and can have a significant impact on patients’
lives,” said Jim Lee, M.D., Ph.D., Group Vice President,
Inflammation & AutoImmunity, Incyte. “We are pleased to be
sharing new data from our Phase 3 TRuE-AD program at the RAD
Virtual Conference. These data provide additional insights on the
potential role ruxolitinib cream could play as a treatment option
for patients living with atopic dermatitis.”
Key abstracts include:
Late-Breaking Oral and Poster
Presentation
Long-Term Safety and Disease Control with Ruxolitinib Cream
in Atopic Dermatitis: Results from Two Phase 3 Studies
Poster Presentations
Long-Term Safety and Disease Control with Ruxolitinib Cream
in Patients with More Severe Atopic Dermatitis: Pooled Results from
Two Phase 3 Studies
Long-Term Safety and Disease Control with Ruxolitinib Cream
Among Patients with Atopic Dermatitis Based on Previous Medication
History: Pooled Results from Two Phase 3 Studies
Predicting Reduction in Lost Productivity and Indirect Costs
Among Patients with Atopic Dermatitis Treated with Ruxolitinib
Cream
Inadequate Disease Control, Treatment Dissatisfaction, and
Quality-of-Life Impairments Among US Patients Receiving Topical
Therapy for Atopic Dermatitis
More information regarding the virtual conference is available
on the RAD website: https://revolutionizingad.com/. Additionally,
meeting abstracts will be published in the British Journal of
Dermatology.
About Ruxolitinib Cream
Ruxolitinib cream is a proprietary formulation of Incyte’s
selective JAK1/JAK2 inhibitor ruxolitinib that has been designed
for topical application. Ruxolitinib cream is currently in Phase 3
development for the treatment of adolescents and adults with atopic
dermatitis (TRuE-AD) and vitiligo (TRuE-V). Incyte has worldwide
rights for the development and commercialization of ruxolitinib
cream.
About Incyte Dermatology
Incyte’s science-first approach and expertise in immunology has
formed the foundation of the company. In Dermatology, the Company’s
research and development efforts are focused on leveraging our
knowledge of the JAK-STAT pathway to identify and develop topical
and oral therapies with the potential to modulate immune pathways
driving uncontrolled inflammation and help restore normal immune
function.
Currently, Incyte is exploring the potential of JAK inhibition
for a number of immune-mediated dermatologic conditions with a high
unmet medical need, including atopic dermatitis, vitiligo and
hidradenitis suppurativa. To learn more, visit the Dermatology
section of Incyte.com.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical
company focused on finding solutions for serious unmet medical
needs through the discovery, development and commercialization of
proprietary therapeutics. For additional information on Incyte,
please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the
matters set forth in this press release, including statements
regarding the presentation of data from the Company’s ongoing
clinical development program for ruxolitinib cream, its TRuE-AD and
TRuE-V programs and its atopic dermatitis, vitiligo and other
dermatology programs generally, and whether or when ruxolitinib
cream will be approved or commercially available in the U.S. or
elsewhere for atopic dermatitis, vitiligo or any other indication,
contain predictions, estimates and other forward-looking
statements.
These forward-looking statements are based on the Company’s
current expectations and subject to risks and uncertainties that
may cause actual results to differ materially, including
unanticipated developments in and risks related to: unanticipated
delays; further research and development and the results of
clinical trials possibly being unsuccessful or insufficient to meet
applicable regulatory standards or warrant continued development;
the ability to enroll sufficient numbers of subjects in clinical
trials; the effects of the COVID-19 pandemic and measures to
address the pandemic on the Company’s clinical trials, supply
chain, other third-party providers and development and discovery
operations; determinations made by the U.S. FDA and other
regulatory authorities outside of the United States; the efficacy
or safety of the Company’s products; the acceptance of the
Company’s products in the marketplace; market competition; sales,
marketing, manufacturing and distribution requirements; and other
risks detailed from time to time in the Company’s reports filed
with the Securities and Exchange Commission, including its annual
report and its quarterly report on Form 10-Q for the quarter ended
March 31, 2021. The Company disclaims any intent or obligation to
update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210612005013/en/
Media Catalina Loveman +1 302 498 6171
cloveman@incyte.com Jenifer Antonacci +1 302 498 7036
jantonacci@incyte.com Investors Christine Chiou +1 302 274
4773 cchiou@incyte.com
Incyte (NASDAQ:INCY)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Incyte (NASDAQ:INCY)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024